Striatal Dopamine Transporter Availability is Associated with Sleep Disturbance among Patients with Bipolar I Disorder: A Single-photon Emission Computed Tomography Study Using [^99mTc] TRODAT-1.

IF 2.4 4区医学 Q3 NEUROSCIENCES

Clinical Psychopharmacology and Neuroscience Pub Date : 2022-11-30 DOI:10.9758/cpn.2022.20.4.768

Tsung-Hua Lu, Shih-Hsien Lin, Huai-Hsuan Tseng, Yen Kuang Yang, Nan Tsing Chiu, Po See Chen

{"title":"Striatal Dopamine Transporter Availability is Associated with Sleep Disturbance among Patients with Bipolar I Disorder: A Single-photon Emission Computed Tomography Study Using [99mTc] TRODAT-1.","authors":"Tsung-Hua Lu, Shih-Hsien Lin, Huai-Hsuan Tseng, Yen Kuang Yang, Nan Tsing Chiu, Po See Chen","doi":"10.9758/cpn.2022.20.4.768","DOIUrl":null,"url":null,"abstract":"Objective: Bipolar disorder (BD) is characterized by the poor sleep quality. Whether the striatal dopamine transporter (DAT) availability is related to sleep quality among patients with BD is unclear.Methods: Fifty-three euthymic patients with BD (24 BD-I and 29 BD-II) and sixty-eight healthy controls were enrolled. The Chinese Version of the Pittsburgh Sleep Quality Index (PSQI) was used, and the availability of DAT was assessed by single-photon emission computed tomography (SPECT) using [99mTc] TRODAT-1.Results: The sleep disturbance component of the PSQI was significantly associated with the level of DAT availability among patients with BD.Conclusion: The striatal dopaminergic activity that contributes to resilience to adversity was associated with sleep pattern among patients with BD.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"20 4","pages":"768-772"},"PeriodicalIF":2.4000,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/42/cpn-20-4-768.PMC9606428.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychopharmacology and Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.9758/cpn.2022.20.4.768","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Bipolar disorder (BD) is characterized by the poor sleep quality. Whether the striatal dopamine transporter (DAT) availability is related to sleep quality among patients with BD is unclear.

Methods: Fifty-three euthymic patients with BD (24 BD-I and 29 BD-II) and sixty-eight healthy controls were enrolled. The Chinese Version of the Pittsburgh Sleep Quality Index (PSQI) was used, and the availability of DAT was assessed by single-photon emission computed tomography (SPECT) using [^99mTc] TRODAT-1.

Results: The sleep disturbance component of the PSQI was significantly associated with the level of DAT availability among patients with BD.

Conclusion: The striatal dopaminergic activity that contributes to resilience to adversity was associated with sleep pattern among patients with BD.

查看原文本刊更多论文

纹状体多巴胺转运体可用性与双相I型障碍患者睡眠障碍相关:使用[99mTc] TRODAT-1的单光子发射计算机断层扫描研究

目的:双相情感障碍(BD)以睡眠质量差为主要特征。纹状体多巴胺转运体(DAT)是否与双相障碍患者的睡眠质量有关尚不清楚。方法:纳入53例心境正常的双相障碍患者(BD- i型24例，BD- ii型29例)和68例健康对照。使用中文版的匹兹堡睡眠质量指数(PSQI)，并通过使用[99mTc] TRODAT-1的单光子发射计算机断层扫描(SPECT)评估数据的可用性。结果:双相障碍患者PSQI中睡眠障碍成分与DAT可得性水平显著相关。结论:纹状体多巴胺能活性与双相障碍患者睡眠模式相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Psychopharmacology and Neuroscience NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY

CiteScore

4.70

自引率

12.50%

发文量

期刊介绍： Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.